




PCT/GB 00 / 02364



INVESTOR IN PEOPLE

GB00/2364



Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

4

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

10th July 2000



The
Patent
Office

1/77

17JUN99 E455233-2 D02029
P01/7700 0.00 - 9914045.1

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

ACC/JR/P32328

2. Patent application number

(The Patent Office will fill in his part)

9914045.1

16 JUN 1999

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

SmithKline Beecham plc
New Horizons Court, Brentford, Middx TW8 9EP,
Great Britain

5500974002

4. Title of the invention

Novel Compounds

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Patents ADP number (if you know it)

CORPORATE INTELLECTUAL PROPERTY

SMITHKLINE BEECHAM PLC
TWO NEW HORIZONS COURT
BRENTFORD
MIDDLESEX TW8 9EP

5500974004

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

| Country | Priority application number (if you know it) | Date of filing (day / month / year) |
|---------|---|--|
|---------|---|--|

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is named as an applicant, or
 - c) any named applicant is a corporate body
- See note (d)

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

| | |
|----------------------------------|----|
| Continuation sheets of this form | 1 |
| Description | 18 |
| Claim(s) | 7 |
| Abstract | 1 |
| Drawings | 5 |

8

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 1/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

We request the grant of a patent on the basis of this application

Signature A C Connell Date 16-Jun-99
A C Connell

12. Name and daytime telephone number of person to contact in the United Kingdom

A C Connell 01279 644395

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- For details of the fee and ways to pay please contact the Patent Office.

CONTINUATION SHE

Reference: ACC/JR/P32328

Further Applicant (s)

Cambridge University Technical Services Ltd

The Old Schools, Cambridge University, CB2 1TS, Great Britain

6956809004

Novel compounds

This invention relates to newly identified spermine:peptide-based surfactant compounds, to the use of such compounds and to processes for their preparation. The invention also relates to the use of the spermine:peptide-based surfactant compounds to facilitate the transfer of compounds into cells for drug delivery.

Surfactants are substances that markedly affect the surface properties of a liquid, even at low concentrations. For example surfactants will significantly reduce surface tension when dissolved in water or aqueous solutions and will reduce interfacial tension between two liquids or a liquid and a solid. This property of surfactant molecules has been widely exploited in industry, particularly in the detergent and oil industries. In the 1970s a new class of surfactant molecule was reported, characterised by two hydrophobic chains with polar heads which are linked by a hydrophobic bridge (Deinega, Y *et al.*, *Kolloidn. Zh.* **36**, 649, 1974). These molecules, which have been termed "gemini" (Menger, FM and Littau, CA, *J. Am. Chem. Soc.* **113**, 1451, 1991), have very desirable properties over their monomeric equivalents. For example they are highly effective in reducing interfacial tension between oil and water based liquids and have a very low critical micelle concentration.


Cationic surfactants have been used *inter alia* for the transfection of polynucleotides into cells in culture, and there are examples of such agents available commercially to scientists involved in genetic technologies (for example the reagent TfxTM-50 for the transfection of eukaryotic cells available from Promega Corp. WI, USA).

The efficient delivery of DNA to cells *in vivo*, either for gene therapy or for antisense therapy, has been a major goal for some years. Much attention has concentrated on the use of viruses as delivery vehicles, for example adenoviruses for epithelial cells in the respiratory tract with a view to corrective gene therapy for cystic fibrosis (CF). However, despite some evidence of successful gene transfer in CF patients, the adenovirus route remains problematic due to inflammatory side-effects and limited transient expression of the transferred gene. Several alternative methods for *in vivo* gene delivery have been investigated, including studies using cationic surfactants. Gao, X *et al.* (1995) *Gene Ther.* **2**, 710-722 demonstrated the feasibility of this approach with a normal human

gene for CF transmembrane conductance regulator (CFTR) into the respiratory epithelium of CF mice using amine carrying cationic lipids. This group followed up with a liposomal CF gene therapy trial which, although only partially successful, demonstrated the potential for this approach in humans (Caplen, NJ. *et al.*, *Nature Medicine*, 1, 39-46, 1995). More recently other groups have investigated the potential of other cationic lipids for gene delivery, for example cholesterol derivatives (Oudrhiri, N *et al.* *Proc. Natl. Acad. Sci.* **94**, 1651-1656, 1997). This limited study demonstrated the ability of these cholesterol based compounds to facilitate the transfer of genes into epithelial cells both *in vitro* and *in vivo*, thereby lending support to the validity of this general approach.

These studies, and others, show that in this new field of research there is a continuing need to develop novel low-toxicity surfactant molecules to facilitate the effective transfer of polynucleotides into cells both *in vitro* for transfection in cell-based experimentation and *in vivo* for gene therapy and antisense treatments. The present invention seeks to overcome the difficulties exhibited by existing compounds.

The invention relates to spermine:peptide-based surfactant compounds having a spermine backbone and having the general structure of formula (I):



(I)


where R_1 and R_3 are hydrogen and R_2 and R_4 , which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):



- 5 where $p1$ is 0 to 5 and $p2$ is 1 to 5, preferably 1; and the values for $p3$ and $p4$, which may be the same or different, are from 0 to 5, preferably 0;
- $A1$, $A3$ and $A4$, which may be the same or different, are amino acids selected from serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and
- $A2$ is an amino acid selected from lysine, ornithine and histidine;
- 10 and R_5 and R_6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH_2) linkage;
- or
- where R_1 and R_3 are hydrogen, R_2 and R_4 , which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the
- 15 spermine backbone by amide or amine bonds, and R_5 and R_6 , which may be the same or different, are peptide groups of formula (II) linked to the spermine backbone by amide bonds;
- or
- a salt, preferably a pharmaceutically acceptable salt thereof.
- 20 When used herein, the term "hydrocarbyl" refers to a group having from 1 to 24 carbon atoms which may be in a straight chain or a branched chain and include a saturated carbocyclic ring having from 3 to 6 carbon atoms and which chain may contain unsaturation (double and/or triple carbon-carbon bonds).
- The amide linkages between the amino acids $A1$, $A2$ and $A3$ in the peptide
- 25 group of formula (II) are standard peptide bonds (α bonds), whereas the amide bond linking the amino acids $A2$ and $A4$ is formed between the amine group on the side chain of $A2$ and the carboxyl group of $A4$ (ϵ bond).
- Preferably, the compound is symmetrical, that is R_1 and R_3 are the same, R_2 and R_4 are the same, and R_5 and R_6 are the same. Symmetrical spermine:peptide-based
- 30 surfactant compounds of the invention are "gemini" surfactants.


In a preferred embodiment A1 in the group of formula (II) is serine or threonine, preferably serine. Preferably A3 and A4 in the group of formula (II) are lysine, ornithine, histidine or arginine.

In a further preferred embodiment the hydrocarbyl group is selected from:



5

In another preferred embodiment the hydrocarbyl group is selected from:



Compounds of the present invention may be prepared from readily available starting materials using synthetic peptide chemistry well known to the skilled person. The scheme shown in Figures 1a and 1b shows a general process for the synthesis of the compounds of the invention wherein the hydrocarbyl groups are linked to the spermine moiety by amine bonds and the scheme shown in Figures 2a and 2b shows a general process for the synthesis of the compounds of the invention wherein the carbonyl groups are linked to the spermine moiety by amide bonds.

The processes shown in Figures 1 and 2 are for the synthesis of symmetrical, that is "gemini", spermine:peptide-based surfactants. Non-symmetrical spermine:peptide-based surfactants of the invention can be prepared by introducing asymmetry, for example at the primary amines of spermine, by using different protecting groups. Suitable nitrogen protecting groups are well known in the art and are described in, for example, "Protective Groups in Organic Chemistry" (T.W.Greene, Wiley-Interscience, New York, 2nd Edition, 1991).

Another aspect of the invention relates to methods for using the spermine:peptide-based surfactant compounds. Such uses include facilitating the transfer of DNA or RNA polynucleotides, or analogs thereof, into a eukaryotic or prokaryotic cell *in vivo* or *in vitro*.

These uses include facilitating transfection of polynucleotides to achieve an antisense knock-out effect, for gene therapy and genetic immunisation (for the generation of antibodies) in whole organisms. Other uses include employing the compounds of the

invention to facilitate the transfection of polynucleotides into cells in culture when such transfer is required, in, for example, gene expression studies and antisense control experiments among others. The polynucleotides can be mixed with the compounds, added to the cells and incubated to allow polynucleotide uptake. After further incubation the cells

5 can be assayed for the phenotypic trait afforded by the transfected DNA, or the levels of mRNA expressed from said DNA can be determined by Northern blotting or by using PCR-based quantitation methods for example the Taqman[®] method (Perkin Elmer, Connecticut, USA). Compounds of the invention offer a significant improvement, typically between 3 and 6 fold, in the efficiency of cellular uptake of DNA in cells in

10 culture, compared with compounds in the previous art. In the transfection protocol, the gemini compound may be used in combination with one or more supplements to increase the efficiency of transfection. Such supplements may be selected from, for example:

(i) a neutral carrier, for example dioleoyl phosphatidylethanolamine (DOPE) (Farhood, H., *et al* (1985) *Biochim. Biophys. Acta* 1235 289);

15 (ii) a complexing reagent, for example the commercially available PLUS reagent (Life Technologies Inc. Maryland, USA) or peptides, such as polylysine or polyornithine peptides or peptides comprising primarily, but not exclusively, basic amino acids such as lysine, ornithine and/or arginine. The list above is not intended to be exhaustive and other supplements that increase the efficiency of transfection are taken to fall within the

20 scope of the invention.

In still another aspect, the invention relates to the transfer of genetic material in gene therapy using the compounds of the invention.

Yet another aspect of the invention relates to methods to effect the delivery of non-nucleotide based drug compounds into cells *in vitro* and *in vivo* using the compounds

25 of the invention.

In a further aspect, the invention relates to methods to facilitate the transfer of a polynucleotide or an anti-infective compounds into prokaryotic or eukaryotic organism for use in anti-infective therapy.

The following definitions are provided to facilitate understanding of certain

30 terms used frequently herein.

"Amino acid" refers to dipolar ions (zwitterions) of the form $^+H_3NCH(R)CO_2^-$. They are differentiated by the nature of the group R, and when R is different from

hydrogen can also be asymmetric, forming D and L families. Amino acids may be natural or un-natural amino acids. There are 20 naturally occurring amino acids where the R group can be, for example, non-polar (e.g. alanine, leucine, phenylalanine) or polar (e.g. glutamic acid, histidine, arginine and lysine). In the case of un-natural amino acids
5 R can be any other group which is not found in the amino acids found in nature.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-
10 stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or
15 more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications have been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA
20 and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Transfection" refers to the introduction of polynucleotides into cells in culture using methods involving the modification of the cell membrane either by chemical or physical means. Such methods are described in, for example, Sambrook et al.,
25 *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). The polynucleotides may be linear or circular, single-stranded or double-stranded and may include elements controlling replication of the polynucleotide or expression of homologous or heterologous genes which may comprise part of the polynucleotide.


30 The invention will now be described by way of the following examples.

EXAMPLES

Example 1 – synthesis of GSC1


Step 1:

5



10 A solution of *N*-carbethoxyphthalimide (4 mmol, 439 mg) in chloroform (5 ml) was added as one portion at room temperature to a stirred solution of spermine (2 mmol, 406.7 mg) in chloroform (5 ml). The mixture was stirred for 1 hour and the solvent was removed, the crude was dried under good vacuum to get the title compound without further purification (Sosnovsky, G. (1986) Zeitschrift für Naturforschung **41b**:122-129).

15 Step 2:




20

The protected spermine 350 mg (0.76 mmol) was dissolved in 10 ml of dry THF, the Lauroyl chloride 3 eq (2.28 mmol) and 2 ml of dry pyridine was added. After refluxing 30 min, the mixture was stirred at room temperature overnight. Solvent was removed, and the crude was dissolved in AcOEt (25 ml) and was washed with saturated bicarbonate (2x20 ml). The organic phase was dried over anhydrous sodium sulfate and evaporated. The resulting oil was chromatographed on silica gel with AcOEt/hexane (1:1 to 4:1) *rf* = 0.20 (AcOEt/hexane 1:1) to yield 490 mg (84 %) of bis-dodecyl as oil

which crystallized as white semi-solid crystal. $^1\text{H-NMR}$ (CDCl_3): 7.9-7.6 *m* (8H (- C_6H_4 -) $_2$); 3.7-3.6 *m* (4H); 3.4-3.2 *m* (8H); 2.3-2.1 *m* (4H); 2.0-1.8 *m* (4H); 1.6-1.4 *m* (8H); 1.3-1.1 *m* (32H); 0.9-0.8 *m* (6H). $^{13}\text{C-NMR}$ (CDCl_3): 173.1, 173.0, 172.9, 172.8, 168.3, 168.2, 134.2, 134.1, 133.9, 133.8, 132.2, 132.1, 132.0, 131.9, 123.4, 123.2, 47.6, 45.7, 45.5, 45.4, 43.5, 43.4, 35.9, 33.9, 33.2, 33.1, 30.9, 29.6, 29.5, 29.4, 29.3, 29.1, 28.3, 28.2, 27.1, 26.7, 26.4, 25.5, 25.4, 25.2, 25.1, 24.9, 22.7, 14.1

Step 3:




10

The bis-phthalimide (400 mg, 0.48 mmol) was dissolved in 20 ml of MeOH, hydrazine monohydrate 0.4 ml was added and the mixture was refluxed 6 H. Solvent was removed, and the crude redissolved in MeOH (20 ml) and 2 ml of concentrated HCl was added. The mixture was refluxed for 30 min, and solvent was removed. The residue was dissolved in aqueous NaOH 10 %, the precipitate was filtrated and wash with 3 amount of cold water. The residue was dried to give 112 mg (41 %) of white powder. $^1\text{H-NMR}$ (MeOH): 3.21 *t* ($^3J = 6.8\text{Hz}$, 4H); 2.6-2.5 *m* (8H); 2.76 *t* ($^3J = 7.5\text{Hz}$, 4H); 1.7-1.5 *m* (12H); 1.4-1.2 *m* (32H); 0.89 *t* ($^3J = 6.9\text{Hz}$, 6H (- CH_3) $_2$).

20

Step 4:




The diamine 100 mg (0.176 mmol), HOBt 2 eq (0.353 mmol, 54 mg), BOC₂Lys 2.4 eq (0.423 mmol, 135mg) and DIPEA 2 eq (0.353 mmol, 62 ml) was dissolved in CH_2Cl_2 (20 ml). The mixture was cooled at -10 °C and DCC 2.4 eq (0.423mmol, 87 mg) was added. The mixture was stirred at -10 °C and allowed to reach room temperature very slowly and set aside overnight. The DCU was removed by filtration, and solvent was

evaporated off. The crude was redissolved in AcOEt (30 ml), was washed successively 4 % NaHCO₃ (2 X 15 ml), 4 % citric acid (2 X 15 ml), water (20 ml) and finally brine (20 ml). Organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness. The residue was chromatographed on silica gel and was eluted with
 5 hexane/AcOEt 1/1 (rf = 0.01) to AcOEt/MeOH 9/1 (rf = 0.6) yield 152 mg (71 %) as oil.
¹H-NMR (CDCl₃): 7.05 sbroad(1H); 6.69 sbroad (1H); 5.6-4.7 m (6H); 4.9-4.1 m (4H); 3.7-3.0 m (16H); 2.2-2.0 m (6H); 2.0-1.0 m (88H); 0.88 t (³J = 6.8Hz, 6H (-CH₃)₂).

Step 5:

10




The tetra-protected Gemini 150 mg (0.12 mmol) was dissolved in CH₂Cl₂/TFA 1/1 (25 ml) and was stirred at room temperature for 0.5 H. Solvent was removed to give the
 15 deprotected compounds as a TFA salt which was exchanged on anionic Dowex 1X8 to get the tetrahydrochloride salt as a sticky oil. The compound was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated three times, to give GSC1. ¹H-NMR (MeOH): 3.8-3.1 m (8H); 3.0-2.8 m (4H); 2.2-2.1 m (4H); 2.0-1.4 m (26H); 1.4-1.2 m (36H); 0.90 t (³J = 6.8Hz, 6H (-CH₃)₂). M/z(H⁺): 823.75; (2H⁺): 412.38.
 20

Example 2 – Synthesis of GSC4


Step 1:

25



The diamine 150 mg (0.265 mmol) was dissolved in 5 % aqueous acetonitrile (10 ml) and triethylamine 2.2 eq (0.6 mmol, 80 μ l) was added. The *N* α ,*N* ϵ -bis-*tert*-butyl-carbamate-L-lysine-L-serine-*O*-succinimide (was built by the usual peptide synthesis) 2 eq (0.528 mmol, 280 mg) in acetonitrile (8 ml) was added slowly. The mixture was stirred 48 h at room temperature, and solvent was removed. The crude was redissolved in AcOEt (30 ml), was washed successively water (2x20 ml), 3 % HCl (2x20 ml), water (20 ml) and finally brine (20 ml). Organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness, to yield 252 mg (68 %). $^1\text{H-NMR}$ (CDCl_3): 4.9-4.1 *m* (4H); 3.6-3.0 *m* (20H); 2.2-2.0 *m* (8H); 2.0-1.0 *m* (80H); 0.88 *t* ($^3J = 6.8\text{Hz}$, 6H (-CH₃)₂).

Step 2:




15

The tetra-protected Gemini 248 mg (0.177 mmol) was dissolved in THF/HClconc 1/1 (25 ml) and was stirred at room temperature for 1 h. Solvent was removed to give the deprotected compounds as a sticky dark oil which was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated several times, to yield 120 mg (60 %) GSC4 as pink powder. $^1\text{H-NMR}$ (MeOH): 4.0-3.9 *m* (2H); 3.5-3.2 *m* ; 3.1-2.9 *m* (4H); 2.5-2.3 *m* (4H); 2.3-2.1 *m* (1H); 2.0-1.5 *m* (20H); 1.4-1.2 *m* (32H); 0.90 *t* ($^3J = 6.8\text{Hz}$, 6H (-CH₃)₂).

Example 3 – Synthesis of GSC40


25

Step 1:



The diamine 120 mg (0.212 mmol), HOBt 2.5 eq. (0.53 mmol, 72 mg), (BOC₂Lys)Lys 2.5 eq. (0.53 mmol, 426 mg) and DIPEA 2.5 eq. (0.53 mmol, 92 μ l) was dissolved in CH₂Cl₂/THF 1/1 (20 ml). The mixture was cooled at -10 °C and DCC 2.4 eq. (0.508 mmol, 105 mg) was added. The mixture was stirred at -10 °C and allowed to reach room temperature very slowly and set aside overnight. The DCU was removed by filtration, and the solvent was evaporated off. The crude product was redissolved in EtOAc (30 ml), was washed successively with 4 % NaHCO₃ (2 X 15 ml), 4 % citric acid (2 X 15 ml), water (20 ml) and finally brine (20 ml). the organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness. The residue was chromatographed on silica gel and was eluted with hexane/EtOAc 1/1 (rf = 0.01) to EtOAc/MeOH 9/1 (rf = 0.55) yield 210 mg (46 %) as oil. ¹H-NMR (CDCl₃): 4.9-4.6 *m* (2H); 4.1-3.9 *m* (4H); 3.5-2.9 *m* (16H); 2.3-2.1 *m* (2H); 1.9-1.0 *m* (164H); 0.88 *t* (³*J* = 6.8Hz, 6H (-CH₃)₂).


Step 2:



The octa-protected gemini 200 mg (0.094 mmol) was dissolved in THF/HClconc 1/1 (20 ml) and was stirred at room temperature for 1 H. The solvent was removed to give the deprotected compounds as a yellow oil which was redissolved in small amount of MeOH and precipitate with ether, the solvent was removed by decantation, this was repeated several times, to yield 130mg (85%) GSC40 as yellow powder.


Example 4 – Synthesis of GSC41

Step 1:



The diamine 200 mg (0.35 mmol) was dissolved in 5 % aqueous acetonitrile (20 ml) and triethylamine 2 eq. (0.7 mmol, 0.1 ml) was added. The bis-(*Nα,Nε*-bis-*ter*-butyl-carbamate-L-lysine)-L-lysine-L-serine-*O*-succinimidate 2 eq (0.71 mmol, 700 mg) in acetonitrile (10 ml) was added slowly. The mixture was stirred 48 H at room temperature, and solvent was removed. The crude product was redissolved in AcOEt (30 ml), was washed successively water (2x20 ml), 3 % HCl (2x20 ml), water (20 ml) and finally brine (20 ml). The organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness, to yield 509 mg (63 %). ¹H-NMR (CDCl₃): 4.9-4.6 *m* ; 4.1-3.9 *m* (4H); 3.6-2.9 *m* (22H); 2.3-2.1 *m* (4H); 2.0-1.0 *m* ; 0.88 *t* (³*J* = 6.8Hz, 6H (-CH₃)₂).


Step 2:



The tetra-protected gemini 499 mg (0.216 mmol) was dissolved in THF/HClconc 1/1 (30 ml) and was stirred at room temperature for 1 H. the solvent was removed to give the deprotected compounds as a sticky brawn oil which was redissolved in small amount of MeOH and precipitated with ether, solvent was removed by decantation, this was repeated several times, to yield 350mg (90%) GSC41 as brown powder.


Example 5 – Synthesis of GSC42

Step 1:



The diamine 200 mg (0.35 mmol) was dissolved in 5 % aqueous acetonitrile (20 ml) and triethylamine 2 eq. (0.7 mmol, 0.1 ml) was added. The bis-(*Nα,Nε*-bis-*ter*-butyl-carbamate-L-lysine)-L-lysine-L-serine-*O*-succinimide 2 eq (0.71 mmol, 700 mg) in acetonitrile (10 ml) was added slowly. The mixture was stirred 48 H at room temperature, and solvent was removed. The crude product was redissolved in AcOEt (30 ml), was washed successively water (2x20 ml), 3 % HCl (2x20 ml), water (20 ml) and finally brine (20 ml). The organic phase was dried over anhydrous sodium sulfate and evaporated to dryness, to yield 522 mg (70 %). ¹H-NMR (CDCl₃): 6.7-6.6 *m* (2H); 5.5-5.3 *m* (2H); 4.9-4.6 *m* (4H); 4.5-4.3 *m* (4H); 4.1-3.9 *m* (4H); 3.5-2.9 *m* (20H); 2.3-2.1 *m* (4H); 1.9-1.0 *m* ; 0.88 *t* (³*J* = 6.8Hz, 6H (-CH₃)₂).


Step 2:



The tetra-protected Gemini 517 mg (0.242 mmol) was dissolved in THF/HClconc 1/1 (30 ml) and was stirred at room temperature for 1 H. The solvent was removed to give the deprotected compounds as a sticky dark oil which was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated several times, to yield 346mg (88%) GSC42 as brown powder.


Example 6 – Synthesis of GSC2

Step 1:



The protected spermine 1.23 g (2.65 mmol) was dissolved in 1,2-dichloroethane (25 ml) and dodecyl aldehyde 2.5 eq. (6.6 mmol, 1.5 ml) was added. After 10 mn, the sodium cyanoborohydride 6 eq. (15.9 mmol, 1 g) was added and the mixture was stirred at room temperature overnight. Then sodium cyanoborohydride 4.5 eq. (750 mg) was added again and mixture was stirred overnight at room temperature. This solution was partitioned between dichloromethane (150 ml) and water (150 ml) and the pH was adjusted to 9. The resulting emulsion was left in a separating funnel for 12 H. Then, the organic phase was dried over sodium sulfate and concentrated. The crude product was chromatographed on silica gel, eluted with EtOAc/Hexane 1/4 to 1/2 (rf: 0.3) containing 0.1% of NEt₃, to yield 540 mg of semi-solid yellow compound (26 %).


Step 2:



The protected spermine 200 mg (0.25 mmol) was dissolved in methanol (10 ml) and hydrazine monohydrate 10 eq (2.5 mmol, 0.13 ml) was added. The mixture was refluxed for 8 H, and the solvent was removed. The crude product was redissolved in 10 ml of methanol and conc. HCl (2 ml) was added, the mixture was refluxed for 30 min, cooled in ice and filtered. The solvent was removed and the crude product redissolved in dichloromethane (30 ml), stirred 30 min at room temperature and the precipitate was removed by filtration. The solution was evaporated and dried under reduce pressure to yield 150 mg GSC2 as a yellow semi-solid compound (88 %).


Example 7 – Synthesis of GSC12

Step 1:



The diamine 143 mg (0.265 mmol) was dissolved in 5 % aq. THF (10 ml) and NEt₃ 0.6 mmol (80 ml), activated peptide 2 eq (0.528 mmol, 282 mg) in THF (5 ml) were added. The mixture was stirred overnight and concentrated. Then, the crude product was dissolved in EtOAc (60 ml) and was washed successively with water (2x20 ml) 3 % HCl (2x20 ml) water (20 ml) brine (20 ml). The organic phase was dried over sodium sulfate and the solvent was evaporated to yield 210 mg of a sticky white compound (58 %).

Step 2:



The tetra-Boc 200 mg (0.146 mmol) was dissolved in THF/conc. HCl 1/1 (20 ml) and was stirred at room temperature for 1 h. The solvent was removed and the crude product was redissolved in small amount of MeOH and precipitated with ether, cooled to -20 °C, the solvent was removed by decantation, this was repeated several times, to yield 150 mg (87 %) GSC12 as a yellow powder.

Example 8. Transfection of recombinant plasmid expressing luciferase into cells using spermine:peptide-based surfactant compounds.

Transfection studies were performed using the adherent cell line CHO-K1 (Puck et al. 1958). Complete medium consisted of MEM alpha medium supplemented with 10 % v/v foetal bovine serum and 1x L-Glutamine. All media and supplements were obtained from Life Technologies.

Stable transfected cell lines expressing β -galactosidase were generated by cotransfection of the plasmid pSV- β -Galactosidase Control Vector (Promega) with the plasmid Selecta Vecta-Neo (R & D Systems) in a 10:1 ratio. Following G418 (Life

Technologies) selection (0.8 mg ml^{-1}), candidate cell lines were tested for β -galactosidase activity (β -Gal Reporter Gene Assay, chemiluminescent; Roche Diagnostics).

***In Vitro* Gene Transfection.**

- 5 Cells were seeded into 96-well MTP plates (Beckton Dickinson) 16-18 hours prior to transfection at an approximate density of 1×10^4 cells per well. For transfection, 64ng of the luciferase reporter gene plasmid, pGL3-Control Vector (Promega) per well, was incubated with various concentrations of the spermine:peptide-based surfactant compounds and complexing agents. After 30 minutes incubation at RT, OPTI-MEM®
- 10 medium (Life Technologies) was added to the transfection mixture and the solution placed on the cells (final volume per well: $100 \mu\text{l}$). Following a 3 hour or over night incubation at 37°C , the transfection solution was replaced with complete medium and the cells incubated further at 37°C . Reporter gene assays were performed according to the manufacturer's guidelines (Roche Diagnostics) approximately 48 hours post
- 15 transfection. Luminescence was measured in a Packard TopCount NXT Microplate Scintillation and Luminescence Counter. For normalization purpose, β -galactosidase activity (β -Gal Reporter Gene Assay, chemiluminescent; Roche Diagnostics) was measured and luciferase activity per β -galactosidase activity was calculated.

Brief description of the drawings

5 Figure 1a and Figure 1b. General scheme for synthesis of spermine:peptide-based surfactant compounds wherein the carbonyl groups (in this instance dodecanoyl) are linked to the spermine moiety by amide bonds. The final compound in Fig 1a is the first compound in Fig 1b.

10 Figure 2a and Figure 2b. General scheme for synthesis of spermine:peptide-based surfactant compounds wherein the carbonyl groups (in this instance dodecanoyl) are linked to the spermine moiety by amine bonds. The final compound in Fig 2a is the first compound in Fig 2b.


15 Figure 3. Transfection of CHO-K1 cells (stable transfected with beta-galactosidase) with spermine:peptide-based gemini surfactants GS-C-1, GS-C-2, GS-C-3, GS-C-4, and GS-C-12. Bars represent the mean cps (counts per second) of 8 experiments \pm the standard error of the mean.

20

25


CLAIMS

1. A spermine:peptide-based surfactant compound having the general structure of formula (I):



(I)

where R_1 and R_3 are hydrogen and R_2 and R_4 , which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):



(II)

where p_1 is 0 to 5 and p_2 is 1 to 5; and the values for p_3 and p_4 , which may be the same or different, are from 0 to 5;

A_1 , A_3 and A_4 , which may be the same or different, are amino acids selected from serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and

A_2 is an amino acid selected from lysine, ornithine and histidine;

and R_5 and R_6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH_2) linkage;

or

where R_1 and R_3 are hydrogen, R_2 and R_4 , which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the

spermine backbone by amide or amine bonds, and R₅ and R₆, which may be the same or different, are peptide groups of formula (II) linked to the spermine backbone by amide bonds;

or

5 a salt, preferably a pharmaceutically acceptable salt thereof.

2. A spermine:peptide-based surfactant compound according to claim 1 which is symmetrical, that is R₁ and R₃ are the same, R₂ and R₄ are the same, and R₅ and R₆ are the same.

10

3. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (II) p₁ is 1 and p₂, p₃ and p₄ are all 0.

4. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein
15 in the peptide group of formula (II) p₁ and p₂ are both 1 and p₃ and p₄ are both 0.

5. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (II) p₁ is 0 and p₂, p₃ and p₄ are all 1.


20 6. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (II) p₁ and p₃ are 0, p₂ is 1 and p₄ is 2.

7. A spermine:peptide-based surfactant compound according to any one of claims 1 to 6 wherein the A₁ is serine.


25

8. A spermine:peptide-based surfactant compound according to any one of claims 1 to 6 wherein the A₂ is lysine.

9. A spermine:peptide-based surfactant compound according to claim 1 wherein the
30 hydrocarbonyl group is selected from:




10. A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from:




5

11. The compound:




12. The compound:

5




13. The compound GSC1 of formula:




10

14. The compound GSC4 of formula:




15

15. The compound GSC40 of formula:




16. The compound GSC42 of formula:




5

17. The compound GSC2 of formula:



10

18. The compound GSC12 of formula:



15

19. The use of a spermine:peptide-based surfactant compound as defined in any one of claims 1 to 15 in facilitating transfection of DNA or RNA polynucleotides or analogs thereof into a eukaryotic or prokaryotic cell *in vivo* or *in vitro*.

20. The use of a spermine:peptide-based surfactant compound according to claim 19 wherein the compound is used in combination with one or more supplements selected from the group consisting of:
- 5 (i) a neutral carrier; or
(ii) a complexing reagent.
21. The use according to claim 20 wherein the neutral carrier is dioleoyl phosphatidylethanolamine (DOPE).
- 10 22. The use according to claim 20 wherein the complexing reagent is PLUS reagent.
23. The use according to claim 20 wherein the complexing reagent is a peptide comprising mainly basic amino acids.
- 15 24. The use according to claim 23 wherein the peptide consists of basic amino acids.
25. The use according to claim 23 or 24 wherein the basic amino acids are selected from lysine and arginine.
- 20 26. The use according to claim 24 wherein the peptide is polylysine or polyornithine.
27. The use according to any one of claims 19 to 26 wherein the oligonucleotides or polynucleotides are transferred into cells to achieve an antisense knock-out effect.
- 25 28. The use according to claim 19 wherein the oligonucleotides or polynucleotides are transferred into cells for gene therapy.
29. The use according to claim 19 wherein the oligonucleotides or polynucleotides are transferred into cells for genetic immunisation (for the generation of antibodies) in whole organisms.
- 30

30. The use according to any one of claims 19 to 26 wherein the oligonucleotides or polynucleotides are transferred into cells in culture.

5 31. The use of a spermine:peptide-based surfactant compound of any one of claims 1 to 18 to facilitate the transfer of a polynucleotide or an anti-infective compounds into prokaryotic or eukaryotic organism for use in anti-infective therapy.

10 32. The use of a spermine:peptide-based surfactant compound of any one of claims 1 to 18 to facilitate the adhesion of cells in culture to each other or to a solid or semi-solid surface.

33. A process for preparing spermine:peptide-based surfactant compounds of claim 1 which process comprises adding amino acids or peptides to a hydrocarbylated spermine backbone.

15

Abstract

Spermine:peptide-based surfactant compounds are disclosed. The compounds are based on a spermine backbone with peptide groups and optionally hydrocarbyl groups linked thereto. Uses of the spermine:peptide-based surfactant compounds and methods for their production are also disclosed.

5

Figure 1a




Figure 1b




Figure 2a




Figure 2b





Figure 3



PC-GR-2011-2304

23177 Alcd. 0-2-0000

Sanctus 0-000000